Idiopathic Pulmonary Fibrosis Market Size 2023

Increase in incidences of cancer worldwide and favorable reimbursement policies provided by manufacturers & insurance providers drive the growth of the market.

PUNE, MAHARASHTRA, INDIA, March 2, 2023 /EINPresswire.com/ -- Idiopathic pulmonary fibrosis is a disease in which lung tissues become thick and stiff over time, which results in reducing the oxygen-carrying capacity of the tissues. It is a type of chronic scarring lung disease characterized by a progressive and irreversible decline in lung function. The tissue in the lungs becomes thick and stiff, which affects the tissue that surrounds the air sacs in the lungs. The most common signs and symptoms of idiopathic pulmonary fibrosis are shortness of breath and a persistent dry, hacking cough. Many affected individuals also experience a loss of appetite and gradual weight loss. Some people with idiopathic pulmonary fibrosis develop widened and rounded tips of the fingers and toes (clubbing) resulting from a shortage of oxygen

Allied Market Research has published a study report with the title Idiopathic Pulmonary Fibrosis Market Size was Valued at USD 3.12 billion in 2020 and is Projected to Garner USD 6.16 billion by 2030, registering a CAGR of 7.0% from 2021 to 2030. The report provides an extensive analysis of changing market dynamics, major segments, value chains, competitive scenarios, and regional landscapes. This research offers valuable guidance to leading players, investors, shareholders, and startups in devising strategies for sustainable growth and gaining a competitive edge in the market.

𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐆𝐫𝐚𝐩𝐡𝐬 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬 𝐇𝐞𝐫𝐞: https://www.alliedmarketresearch.com/request-sample/4407

Increase in incidences of cancer worldwide, favorable reimbursement policies provided by manufacturers & insurance providers, and rise in cigarette smoking drive the growth of the global idiopathic pulmonary fibrosis market. However, the unavailability of the proper treatment options restrains the market growth. On the other hand, rise in number of pipeline drugs and untapped potential in developing countries present new opportunities in the coming years.

𝐓𝐨𝐩 𝐈𝐝𝐢𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬

• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Boehringer Ingelheim
• GNI Group Ltd
• F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
• Shiongi co Ltd
• Mission Therapeutics
• Biogen, Inc.
• Galapagos NV
• FibroGen, Inc.

𝐈𝐝𝐢𝐨𝐩𝐚𝐭𝐡𝐢𝐜 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐜𝐚𝐧 𝐛𝐞 𝐝𝐨𝐧𝐞 𝐛𝐚𝐬𝐞𝐝 𝐨𝐧 𝐬𝐞𝐯𝐞𝐫𝐚𝐥 𝐟𝐚𝐜𝐭𝐨𝐫𝐬, 𝐢𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠:

By Drug Type

• Pirfenidone
• Nintedanib

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Providers

Based on region, North America contributed to the highest market share in 2020, holding more than two-fifths of the global idiopathic pulmonary fibrosis market, and is projected to continue its lead in terms of revenue by 2030. This is attributed to high expenditure on R&D activities, the presence of major players & their product availability, and the well-established healthcare infrastructure in the region. However, Asia-Pacific is expected to manifest the fastest CAGR of 8.9% during the forecast period, owing to improvement in R&D facilities and rapidly developing economic conditions.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/purchase-enquiry/4407

Key Findings Of The Study

• By drug type, the pirfenidone segment is expected to experience rapid growth in the idiopathic pulmonary fibrosis market, and is projected to grow at a CAGR of 7.2% from 2021 to 2030
• Nintedanib is projected to grow at a CAGR of 6.6% during the forecast period.
• Region-wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 8.9% during the forecast period.

Our Market Research Solution Provides You Answer to Below Mentioned Question:

• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
• How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
• Which region has more opportunities?

By Region Outlook

• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Top Trending Report:

• AT-Home Testing Market: https://www.alliedmarketresearch.com/at-home-testing-market-A31866
• Resuscitation Devices Market: https://www.alliedmarketresearch.com/resuscitation-devices-market-A11454
• Molecular diagnostics market: https://www.alliedmarketresearch.com/molecular-diagnostics-market
• MRI Coils Market: https://www.alliedmarketresearch.com/mri-coils-market-A14839
• Digital PCR Market: https://www.alliedmarketresearch.com/digital-polymerase-chain-reaction-market
• Dental Equipment Market: https://www.alliedmarketresearch.com/dental-equipment-market

Contact Details:

David Correa
USA/Canada (Toll-Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Analytics LLP
+ + +1 503-894-6022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.